Symbol | Exchange | Currency |
|---|
Nuvalent, Inc.(Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today...
Investing.com - Nuvalent (NASDAQ: NUVL) reported first quarter EPS of $-0.49, $0.06 worse than the analyst estimate of $-0.43. Revenue for the quarter came in at $0.00 versus the...
Nuvalent Inc (NUVL) has filed mixed shelf of: Debt Securities Class A Common Stock Preferred Stock Units Warrants
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase ½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Neutral | Sell | Strong Sell | Buy |
| Technical Indicators | Sell | Strong Buy | Sell | Strong Sell | Strong Buy |
| Summary | Neutral | Buy | Sell | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 190.41 | 192.36 | 187.15 | -1.81 | -0.94% | 115.62M | NASDAQ | |||
| 160.25 | 160.34 | 157.85 | +1.32 | +0.83% | 56.97M | NASDAQ | |||
| 60.90 | 61.01 | 59.91 | +0.98 | +1.64% | 12.65M | NYSE | |||
| 206.01 | 207.58 | 203.55 | +1.73 | +0.85% | 27.63M | NASDAQ | |||
| 105.44 | 105.49 | 103.84 | -0.16 | -0.15% | 30.02M | NASDAQ | |||
| 280.57 | 280.63 | 275.28 | +2.91 | +1.05% | 28.01M | NASDAQ | |||
| 40.39 | 40.46 | 39.87 | +0.21 | +0.52% | 17.13M | NYSE | |||
| 97.95 | 99.52 | 96.74 | -2.33 | -2.32% | 64.14M | NASDAQ | |||
| 98.13 | 98.30 | 96.40 | -0.58 | -0.59% | 55.74M | NASDAQ | |||
| 156.56 | 158.27 | 153.56 | -3.42 | -2.14% | 2.51M | NASDAQ | |||
| 267.79 | 271.67 | 263.55 | -4.12 | -1.52% | 45.08M | NASDAQ | |||
| 8.20 | 8.35 | 8.06 | -0.13 | -1.56% | 17.87M | NYSE | |||
| 106.07 | 106.16 | 104.74 | -0.18 | -0.17% | 25.05M | NASDAQ | |||
| 44.98 | 45.58 | 44.24 | -0.81 | -1.77% | 11.13M | NYSE | |||
| 10.33 | 10.33 | 10.33 | +0.050 | +0.49% | 193.00 | NYSE |